In oral immediate-release tablet programs for menadione sodium bisulfite **96.0–98.0%** pharma grade, the drug substance is controlled by the USP-NF monograph for Menadione Sodium Bisulfite and by internal specifications that include assay on the dried basis, loss on drying, residue-on-ignition, elemental impurity screening per ICH Q3D Table A.2.1, and residual solvent profiling per ICH Q3C with Class 3 solvents not exceeding **5 000 ppm**. The trihydrate lattice of the sodium bisulfite adduct contains approximately **16.4%** theoretical water, a value that makes Karl Fischer moisture determination an essential in-process control during dispensing, granulation, and compression. Wet granulation is the dominant manufacturing route when the tablet dose falls between **5 mg** and **25 mg** per unit, because the API particle size required for direct compression—milled to **D90 ≤ 75 μm** and dried to **LOD ≤ 0.5%**—increases exposed surface area and accelerates photodegradation unless amber-light production suites and opaque intermediate containers are maintained. The API addition ratio for immediate-release tablet cores falls between **4% w/w** and **15% w/w** of the core weight. A representative **10 mg** tablet with target core weight **120 mg** contains **8.3% w/w** menadione sodium bisulfite, **45–60%** microcrystalline cellulose PH102, **10–20%** lactose monohydrate or anhydrous dicalcium phosphate, **3–5%** croscarmellose sodium, **3–5%** povidone K30, and **0.5–1.0%** magnesium stearate; higher-dose **25 mg** tablets reduce lactose fraction but maintain the total excipient-to-API ratio within the compressibility window. Granulation proceeds in a high-shear granulator (Diosna P1/6 or GEA PMA 25) with impeller speed **250–350 rpm**, chopper speed **1 500–2 000 rpm**, and a binder solution of purified water containing **5% w/w** povidone K30 added at **10–15 g/min** per kilogram of dry powder over **3–5 minutes**; the endpoint is visual and torque-based to avoid over-massing that results in dense granules with poor disintegration. Drying is executed in a fluid bed dryer (Glatt GPCG 5) with inlet air at **55–65 °C** and product-bed temperature maintained below **40 °C** to prevent thermal dissociation of the bisulfite adduct and premature yellowing; granule moisture is driven to **1.0–2.0%** LOD as a release criterion. Dried granules pass through a conical mill fitted with a **610–813 μm** round or Conidur screen, are blended in a bin blender at **25 rpm** for **15 minutes**, lubricated with magnesium stearate for an additional **3 minutes** to avoid over-lubrication, and compressed on a rotary tablet press at **8–14 kN** main compaction force to hardness **60–90 N**. Aqueous film coating with a hypromellose/titanium dioxide system is applied in a perforated pan coater at exhaust air temperature **38–42 °C** to a weight gain of **2–3% w/w**, providing both light protection for the naphthoquinone chromophore and a moisture barrier. Release testing includes USP <711> Dissolution using Apparatus 2 (paddle) at **50 rpm** in **900 mL** purified water at **37.0 ± 0.5 °C** with **Q ≥ 80%** at **30 minutes**, USP <701> Disintegration in water at **37 °C** with limit **NMT 15 minutes**, and USP <905> Uniformity of Dosage Units with acceptance value **AV ≤ 15.0**. Stability studies per ICH Q1A(R2) cover long-term **25 °C/60% RH**, intermediate **30 °C/65% RH**, and accelerated **40 °C/75% RH** conditions, with photostability per ICH Q1B Option 2 performed on the final commercial pack. Finished product types include **5 mg**, **10 mg**, and **25 mg** film-coated immediate-release tablets for oral administration in patient populations with vitamin K deficiency, hypoprothrombinemia, or anticoagulant reversal protocols.

How Does Low-Dose Capsule Filling Preserve Content Uniformity for a Light-Sensitive Naphthoquinone Adduct?

Hard gelatin and HPMC capsule presentations are selected when compression tooling wear, ejection force spikes, or coating defects reduce yield during long tableting campaigns, and when clinical flexibility requires a simplified excipient matrix. The principal technical obstacle in capsule formats is content uniformity at **5–10 mg** dose levels, solved by geometric dilution in two passes: first, a **1:10** API-to-diluent trituration in a mortar or small-volume blender; second, a further **1:10** dilution to target concentration before final blending. Capsule fill weights range from **120 mg** to **200 mg**, yielding API mass fractions of **2.5–8.3% w/w**; diluent selection is restricted to pharmaceutical-grade mannitol, pregelatinized starch, or microcrystalline cellulose, and lactose monohydrate is excluded when the HPMC capsule shell exhibits equilibrium moisture above **6%** at **40% RH** to avoid moisture exchange with the hygroscopic API salt. Blend preparation takes place in a V-blender or bin blender at **25 rpm** for **20–25 minutes** with the intensifier bar disabled, as electrostatic charging of the fine API fraction causes segregation when the intensifier bar is active. Filling is performed on a dosator-type or tamping-pin machine (MG2 Planeta, Bosch GKF 1500) under controlled humidity of **35–45% RH** and sodium-vapor or amber lighting to limit photochemical degradation during the **30–60 minute** exposure window. In-process control includes individual capsule weight variation limits of **±5%** and content uniformity per USP <905> with **AV ≤ 15.0**; disintegration follows USP <701> with limit **NMT 30 minutes** for hard gelatin and HPMC capsules in water at **37 °C**, and dissolution testing per USP <711> Apparatus 2 at **50 rpm** confirms **Q ≥ 80%** at **30 minutes**. Compliance for capsule manufacture includes 21 CFR 211.110 in-process sampling, ICH Q3D elemental impurity control, and the USP-NF Menadione Sodium Bisulfite monograph. Finished product types comprise **5 mg** and **10 mg** hard gelatin capsules in size **3** or **4**, and identical strength HPMC capsules for vegetarian or religious-dietary markets.Across the six downstream manufacturing tracks, the compliance burden shifts by dosage form and route of administration. The matrix below summarizes the controlling pharmacopoeial chapters, GMP regulations, and auxiliary standards that buyers of pharma grade menadione sodium bisulfite **96–98%** must verify in supplier dossiers.

Manufacturing Scenario	Pharmacopoeial & ICH Control	GMP & Regulatory Reference	Primary Quality Test Methods	Container Closure Requirement
Oral immediate-release tablets	USP Menadione Sodium Bisulfite monograph; ICH Q3D, Q3C, Q1A(R2), Q1B	21 CFR 210/211; 21 CFR 211.110, 211.166	USP <905>, USP <701>, USP <711>, USP <786>	Opaque HDPE bottles or aluminum/PVC blister with light barrier
Hard gelatin/HPMC capsules	USP Menadione Sodium Bisulfite monograph; ICH Q3D	21 CFR 210/211	USP <905>, USP <701>, USP <711>	Opaque HDPE bottles; gelatin/HPMC capsule shell
Dispersible granules/sachets	USP Menadione Sodium Bisulfite monograph; ICH Q1B	21 CFR 210/211; WHO guidance for pediatric dispersible oral dosage forms	USP <786>, USP <711>, dispersibility ≤ 3 min	Aluminium foil laminate sachet (PE/Al/PE)
Injectable parenteral solutions	USP Menadione Sodium Bisulfite monograph; USP <1>; ICH Q1B, Q3B	21 CFR 210/211; EU GMP Annex 1; ISO 15378	USP <71>, USP <85>, USP <788>, USP <791>, Ph. Eur. 2.2.2	Type I amber borosilicate glass ampoules/vials; USP <660>, USP <381>
Fixed-dose combination blends	Component monographs; ICH Q3D	21 CFR 210/211	USP <905>, USP <711>, USP <701>	Opaque blister or bottle with desiccant
Veterinary parenteral/oral powders	USP veterinary monograph; VICH GL18, GL11	21 CFR 514; EU Regulation 2019/6; 21 CFR 210/211	USP <71>, USP <85>, USP <788> for injectables; blend uniformity for oral powders	Amber vials (parenteral); multi-layer paper/PE/Al bags (oral powder)

Dispersible and effervescent granule presentations of menadione sodium bisulfite serve geriatric and pediatric populations in which solid-unit swallowing is impaired; the formulation boundary explicitly excludes neonatal administration because menadione derivatives carry a documented risk of hemolytic anemia, hyperbilirubinemia, and kernicterus in neonates. The API is incorporated at **0.5–5.0% w/w** of finished granule mass, with typical sachet unit doses of **5 mg** or **10 mg** delivered from **1–2 g** fill weight. Top-spray fluid bed granulation (Glatt GPCG 5 or equivalent) processes a dry blend of mannitol, sucrose, pregelatinized starch, sodium starch glycolate, and menadione sodium bisulfite at inlet air temperature **50–65 °C**, product bed temperature **28–34 °C**, and spray rate adjusted to maintain exhaust humidity below **70% RH**; the aqueous binder comprises **5% w/w** povidone K30 or hypromellose E5 in purified water. Granules are dried to **LOD ≤ 2.0%**, milled to a target particle-size distribution of **180–850 μm** controlled by USP <786> sieve analysis, and then blended with flavor, sweetener (sucralose or mannitol), and **0.5%** colloidal silicon dioxide as flow aid prior to sachet filling on horizontal form-fill-seal equipment with heat-seal integrity verified per supplier procedure. Dispersibility testing follows the WHO concept for pediatric dispersible oral dosage forms: a single sachet dose disperses in **100 mL** purified water at **25 °C** with gentle manual swirling within **3 minutes** and leaves no residue on a **710 μm** sieve. Dissolution of the dispersed granules uses USP <711> Apparatus 2 (paddle) at **50 rpm** in **900 mL** purified water with **Q ≥ 80%** at **30 minutes**. The finished sachets employ aluminium foil laminate construction (polyethylene/aluminium/polyethylene) with an outer paper layer, providing a full UV barrier per ICH Q1B; stability protocols include accelerated **40 °C/75% RH** for **6 months**, long-term **25 °C/60% RH** for **24 months**, and an in-use stability study covering **7 days** after first opening at **30 °C/65% RH** to account for patient behavior in hot-humid climates. Finished product types include **5 mg** and **10 mg** dispersible granules in single-dose sachets and bulk oral powder for reconstitution in hospital pharmacy settings.

Injectable Parenteral Solutions Operate Within a Narrow Photothermal Stability Boundary

Menadione sodium bisulfite injection formulations rely on the bisulfite adduct to confer aqueous solubility to the otherwise hydrophobic menadione naphthoquinone nucleus; this adduct is reversible and pH-dependent, making the aqueous stability window the primary formulation constraint. At pH above **6.5**, the adduct dissociates and free menadione precipitates as yellow crystalline solid; at pH below **4.0**, sulfite species evolve sulfur dioxide and accelerate container-closure interaction. The working pH range is set at **5.0–6.5**, buffered with **0.1 M** citrate or acetate and adjusted with dilute hydrochloric acid or sodium hydroxide. API concentration spans **2–20 mg/mL**, with **10 mg/mL** as the most common commercial strength, corresponding to **0.2–2.0% w/v** drug substance loading. Sodium metabisulfite at **0.1–0.2% w/v** is added as sacrificial oxygen scavenger, sodium chloride or dextrose adjusts osmolality to **280–320 mOsm/kg**, and benzyl alcohol at **1.0–1.5% v/v** serves as antimicrobial preservative solely in multi-dose container presentations where justified under applicable multi-dose container regulatory requirements. The following pH-stability gradient, derived from routine forced-degradation screening used in injectable formulation development, demonstrates the process window:

Process pH	Visual Observation	Adduct Integrity	Downstream Consequence
4.0	Clear, minor SO₂ evolution	Partially intact	Process reject due to gas evolution and closure interaction
4.5	Clear, slight SO₂ odor	Intact	Acceptable lower boundary with nitrogen overlay
5.0	Clear, no odor	Intact	Preferred formulation pH
5.5	Clear, no odor	Intact	Preferred formulation pH
6.0	Clear, no odor	Intact	Acceptable upper boundary
6.5	Clear to very slightly opalescent	Reduced	Upper limit; precipitation risk increases above this value
7.0	Yellow precipitate	Dissociated	Product failure due to menadione precipitation

Manufacturing uses nitrogen-sparged Water for Injection (WFI) equilibrated to **20–25 °C**; dissolved oxygen is maintained below **0.5 mg/L** during batching. Sequential filtration comprises a **0.45 μm** polyethersulfone prefilter followed by **0.22 μm** PVDF membrane filters, with filter integrity testing by bubble point or diffusion performed before and after filtration per EU GMP Annex 1. Filling occurs in ISO 5 (Class 100) unidirectional laminar flow under amber lighting. Containers are Type I borosilicate glass amber ampoules (USP <660>) or Type I vials sealed with bromobutyl elastomeric closures (USP <381>); headspace is purged with nitrogen to residual oxygen below **1.0% v/v**. Terminal sterilization in a saturated-steam autoclave at **121 °C** with F0 **≥ 8 minutes** may be applied for selected formulations, but this route accelerates color development from pale yellow to brown; aseptic processing without terminal heat is preferred when the marketing authorization dossier has adopted a color specification at **420 nm** that terminal sterilization cannot meet. Where terminal sterilization is claimed, thermal challenge studies include F0 values of **8**, **12**, and **15 minutes** to establish the color-degradation slope. Parenteral quality control includes USP <71> Sterility by membrane filtration, USP <85> Bacterial Endotoxins with a K/M-derived limit (K = **5 EU/kg** for parenteral administration, M = maximum dose in mL per kg per hour), USP <788> Particulate Matter with small-volume injection limits of **6 000 per container** at ≥ **10 μm** and **600 per container** at ≥ **25 μm**, and Ph. Eur. 2.2.2 Method II color comparison against defined comparator solutions. pH is measured per USP <791> with acceptance **5.0–6.5**; assay follows the USP monograph procedure using UV-Vis or HPLC; degradation products are quantified by an ion-pair HPLC method with limits set per ICH Q3B reporting and qualification thresholds. Photostability follows ICH Q1B Option 2: amber Type I glass ampoules and secondary cartons are exposed to **1.2 million lux-hours** visible light and **200 W·h/m²** near-UV, with degradation-product profiling demonstrating no new impurity above threshold. In-use stability for multi-dose vials covers **28 days** at **25 °C/60% RH** after first puncture, with preservative efficacy tested per USP <51>. Finished product types include **1 mL** and **2 mL** amber ampoules containing **10 mg/mL** menadione sodium bisulfite for intramuscular or slow intravenous administration, and multi-dose vials with preservative for clinic use.

When Ascorbic Acid and Ferric Ion Donors Appear in Fixed-Dose Combination Blends

Fixed-dose combination tablets and capsules pairing menadione sodium bisulfite with B-complex vitamins, ascorbic acid, and mineral salts introduce oxidative incompatibilities that mandate separate granulation trains, barrier coating, and strict sequencing of blend additions. Ascorbic acid reduces the quinone ring of menadione, while soluble ferric and cupric ions catalyze electron transfer and accelerate degradation; direct co-granulation therefore fails on stability. The process solution used on production-scale equipment is to granulate the vitamin K3 fraction separately with a non-reducing diluent such as anhydrous dicalcium phosphate, then apply a **2–3% w/w** hypromellose barrier coating before blending with the mineral-containing granule. API addition ratio in the final FDC blend ranges from **0.5–5.0% w/w**, scaled to deliver **5–25 mg** menadione sodium bisulfite per unit. Multi-stage blending uses a bin blender at **15 rpm** for **20 minutes**; the mineral premix is added last to minimize contact residence time. Compression runs on a rotary tablet press at **10–16 kN** main compaction to hardness **70–110 N**; direct compression of the final blend is not recommended when the mineral fraction exceeds **30% w/w** because of segregation tendency. Prenatal multivitamin products in many regulated markets substitute phytonadione (vitamin K1) for menadione due to neonatal safety concerns; pharmaceutical FDC products containing menadione sodium bisulfite are therefore restricted to non-prenatal adult therapeutic combinations and specific regional compendial markets. Compliance includes USP <905>, USP <711>, USP <701>, ICH Q3D, 21 CFR 211, and the individual USP monographs for each component vitamin and mineral salt. Finished product types include combination tablets, bilayered tablets where API segregation risk is eliminated by physical separation, and combination capsules with API pre-granulation.

At 50 mg/mL Parenteral Concentration in Canine Rodenticide Toxicosis Management

Veterinary pharmaceutical presentations of menadione sodium bisulfite pharma grade target anticoagulant rodenticide toxicosis in companion animals (bromadiolone, difethialone, warfarin-type baits) and adjunct therapy during sulfaquinoxaline coccidiostat treatment in poultry. Parenteral veterinary injectables are commonly manufactured at **50 mg/mL** (**5% w/v** API), requiring higher concentration stability than human injectables and therefore stricter control of pH (**6.0–7.0**), nitrogen blanketing, and terminal sterilization at **121 °C** with F0 **≥ 12 minutes** to account for heavier bioburden from large-volume farm use. Published veterinary clinical data indicate an initial intramuscular dose of **2.5–5 mg/kg** body weight, followed by **2.5 mg/kg** orally every **12 hours** until prothrombin time normalizes; additional subcutaneous doses are guided by serial coagulation monitoring. The addition ratio for oral veterinary powders (administered via feed or drinking water) ranges from **0.1–1.0% w/w** API in the final feed premix, with dosing typically **2–4 g** menadione sodium bisulfite per ton of feed for poultry coccidiosis adjunct regimens. Manufacturing of oral powder proceeds by dry blending in ribbon blenders or plow mixers, with API particle size **≤ 150 μm** to ensure homogeneity; packaging in multi-layer paper/polyethylene/aluminium bags provides moisture and light barrier. Compliance for veterinary products includes 21 CFR 514 for new animal drug approvals, EU Regulation 2019/6 for veterinary medicinal products, VICH GL18 for residual solvents, VICH GL11 for target animal safety, and 21 CFR 210/211 for finished pharmaceutical manufacturing. Quality testing for parenteral veterinary presentations aligns with USP <71>, USP <85>, and USP <788>; oral powders require blend uniformity per compendial powder-mix testing and moisture control below **2.0%**. Finished product types comprise **50 mg/mL** veterinary injection in amber vials, oral water-soluble powders, and feed premix powders for poultry and swine.